Clinical Trials in the Management of Anal Cancer

ABSTRACT

Our understandings of anal canal cancer pathogenesis and treatment have undergone significant changes due to continuing research into its pathogenesis and the results of major clinical trials conducted over the past 20 years. Anal canal cancer can be cured by combined modality chemoradiation therapy, a treatment that preserves continence and reserves abdominoperineal resection of the rectum and anal canal in patients with recurrent or residual disease after primary chemoradiotherapy. The research into more effective, less toxic therapies is continuing. Future challenges include an increasing incidence of human papillomavirus infection, the AIDS epidemic, diagnosis of early disease, and optimization of chemotherapy and radiation regimens. This article aims to provide a summary of recently completed and ongoing clinical trials in the management of anal canal cancer.

KEYWORDS

Anal canal cancer - chemotherapy - radiation therapy

REFERENCES

• 1 Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008.  CA Cancer J Clin. 2008;  58(2) 71-96
• 2 Palefsky J M. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem.  AIDS. 1994;  8(3) 283-295
• 3 Klas J V, Rothenberger D A, Wong W D, Madoff R D. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.  Cancer. 1999;  85(8) 1686-1693
• 4 Greenall M J, Quan S H, Stearns M W, Urmacher C, DeCosse J J. Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results.  Am J Surg. 1985;  149(1) 95-101
• 5 Nigro N D, Vaitkevicius V K, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report.  Dis Colon Rectum. 1974;  17(3) 354-356
• 6 Leichman L, Nigro N, Vaitkevicius V K et al.. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.  Am J Med. 1985;  78(2) 211-215
• 7 Doci R, Zucali R, La Monica G et al.. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.  J Clin Oncol. 1996;  14(12) 3121-3125
• 8 UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research . Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin.  Lancet. 1996;  348(9034) 1049-1054
• 9 Bartelink H, Roelofsen F, Eschwege F et al.. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.  J Clin Oncol. 1997;  15(5) 2040-2049
• 10 Flam M, John M, Pajak T F et al.. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.  J Clin Oncol. 1996;  14(9) 2527-2539
• 11 Ajani J A, Winter K A, Gunderson L L et al.. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.  JAMA. 2008;  299(16) 1914-1921
• 12 Oehler-Jänne C, Huguet F, Provencher S et al.. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.  J Clin Oncol. 2008;  26(15) 2550-2557
• 13 Glynne-Jones R, Meadows H, Wan S National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group et al. EXTRA—a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.  Int J Radiat Oncol Biol Phys. 2008;  72(1) 119-126